iShares US Power Infrastructure ETF vs uniQure N.V. Ordinary Shares — how do they compare? iShares US Power Infrastructure ETF trades at $24.99 (market cap $448.01M), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 3.3× iShares US Power Infrastructure ETF's market cap, and iShares US Power Infrastructure ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Power Infrastructure ETF for 19 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| POWR | QURE | |
|---|---|---|
Market Cap | $448.01M | $1.48B |
Volume | 115,109 | 2,488,780 |
Sector | Sector/Thematic | Health |
52-Week High | $28.22 | $70.59 |
52-Week Low | $23.20 | $9.03 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
POWR trades at $25.68, up 0.75% with a bullish technical signal from moving averages. The company reported $256.66M revenue in 2014 but posted a net loss of -$6.99M, with negative EBITDA of -$952K. Cash flow trends show volatility, with 2014 net cash flow at -$17.14M. The stock faces fundamental challenges despite technical strength, with debt-to-asset ratio at 7.09 indicating high leverage.
The outlook remains mixed with technical indicators supporting near-term upside, but fundamental weaknesses in profitability and cash flow generation pose significant risks. Investment opportunity exists if operational improvements materialize, while current financial metrics suggest caution for value-oriented investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →